Krystal Biotech, Inc. Common Stock (KRYS) Financials
Key financial figures for Krystal Biotech, Inc. Common Stock (Q2 2026).
Krystal Biotech, Inc. reported revenue of $119.2 million for Q2 FY2026, up 24.1% from the same period a year earlier. Net income was $54.8 million, or $1.79 per share. Operating margin came to 49%, against 40.93% a year earlier. Free cash flow for the period was $71.2 million. Across the last 5 reported quarters, quarterly revenue has risen from $96.0 million in Q2 FY2025 to $119.2 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Krystal Biotech, Inc. are on the SentiSense financials page.
- Revenue
- $119M
- Net Income
- $55M
- EPS
- $1.85
- Total Assets
- $1.5B
- Operating Cash Flow
- $75M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $119M | $55M | $1.79 | 49% | $71M |
| Q1 FY2026 | $116M | $56M | $1.83 | 46.14% | $73M |
| Q4 FY2025 | $107M | $51M | $1.70 | 41.49% | $75M |
| Q3 FY2025 | $98M | $79M | $2.66 | 42.3% | $38M |
| Q2 FY2025 | $96M | $38M | $1.29 | 40.93% | $51M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $389M | $205M | $6.84 | 41.45% | $189M |
| FY2024 | $291M | $89M | $3.00 | 22.61% | $119M |
| FY2023 | $51M | $11M | $0.39 | -216.43% | -$101M |
Frequently asked questions
What was Krystal Biotech, Inc.'s revenue last quarter?
Krystal Biotech, Inc. reported revenue of $119.2 million for Q2 FY2026, up 24.1% from the same period a year earlier.
Is Krystal Biotech, Inc. profitable?
Yes. Krystal Biotech, Inc. reported net income of $54.8 million for Q2 FY2026, a net margin of 45.94% on revenue.
How has Krystal Biotech, Inc.'s margin trended?
Operating margin was 49% in Q2 FY2026, compared with 40.93% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Krystal Biotech, Inc. generate?
Krystal Biotech, Inc. generated free cash flow of $71.2 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Krystal Biotech, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.